Sun Pharma Q1 FY27 Earnings Call: Reiterates High Single-Digit Revenue Growth, Gross Margin Expands to 80.5% (SUNPHARMA)

Sun Pharmaceutical Industries Ltd held its Q1 FY27 earnings call on July 31, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials — Revenue Up 10% YoY, Gross Margin Expands

• Consolidated sales of Rs.1,51,836 million — up 10.1% YoY vs Q1 FY 2025-2026, driven by broad-based growth across India formulations and innovative medicines.
• Gross margin improved to 80.5% — management attributed the expansion to a favorable product mix, with higher contribution from branded generics and innovative medicines in Q1 FY 2026-2027.
• EBITDA of Rs.44,177 million (28.9% margin) — up 2.7% YoY; margin was slightly lower YoY but, adjusted for the lenalidomide benefit in Q1 FY 2025-2026, margin was higher.
• Adjusted net profit of Rs.30,894 million — reported net profit was Rs.28,948 million after exceptional items of Rs.1,670 million booked for Organon acquisition-related costs; EPS of Rs.12.10 for Q1 FY 2026-2027.
• India formulation sales of Rs.54,749 million — up 16% YoY, accounting for 36.1% of total consolidated sales, with 50% of growth driven by volume and new product launches.
• US business sales of $427 million — down 9.7% YoY, representing 26.6% of consolidated sales, as growth in innovative medicines was offset by generic pricing erosion and competition.

Generics Decline from Lenalidomide; Specialty Launches Gain Traction

• US generic revenue fell sharply QoQ and YoY — Mr. Richard Astore attributed the decline primarily to Lenalidomide competition, with a slight base-business decline from competition on a few products in Q1 FY 2026-2027.
• Five new generic products launched in the US — these launches will contribute to growth in Q1 FY 2026-2027, with additional launches planned for the current quarter; management declined to provide specific US generic growth guidance.
• 100+ ANDAs in the pipeline — management stated the company continues to invest in generic R&D to generate cash flows from the US generics business once past the current adverse regulatory cycle.
• Global specialty revenue flat to slightly down sequentially — despite two major product launches in the last 6-9 months, management cited the early growth curve and seasonality in one product (Levulan for actinic keratosis, with similar seasonality expected in Q2 FY 2026-2027).
• Lexcelvi (deuruxolitinib) surpassed 1,000 prescribers — recorded its strongest month of prescriptions since launch in June 2026; payer access improved with majority of covered lives secured and an important plan added in Q1 FY 2026-2027.
• Unloxet (Unloxo) gaining formulary access at cancer centers — launched earlier in FY 2026-2027, with month-over-month growth as health systems add it to formularies driven by a differentiated mechanism of action and lack of grade 4/5 immune-related adverse events.

Domestic Growth Accelerates; Emerging Markets Hold Steady

• India business grew 16% in Q1 FY 2026-2027 — broad-based performance across all business units, supported by prior field force expansion into tier-2 and tier-3 cities and new prescription-building efforts.
• Sun Pharma ranked #1 in IPM with 8.5% market share — per Pharmarack MAT June 2026, up from 8.2% in the prior period; the company is #1 by prescription volumes (SMSRC) and #1 in 12 doctor categories.
• Volume growth of 5.4% vs IPM volume growth of 2% — management noted 40% of total growth came from volume and 20% from new products, together contributing 60% of overall growth, indicating healthy prescription generation.
• Five new products launched in India — during Q1 FY 2026-2027, including entry into the semaglutide injectable market where Sun Pharma holds the #2 position among generic players with the only auto-injector device.
• Emerging markets revenue of $311 million, up 4.2% YoY — contributed 19.4% of consolidated revenue; growth was driven by branded generics and innovative medicines (Ilumia in Romania and Brazil), with Mr. Kirti Ganorkar citing geopolitical issues and difficult macroeconomic conditions in certain countries.
• ROW (rest-of-world) revenue flat at ~$218 million — for the second consecutive quarter (Q4 FY 2025-2026 and Q1 FY 2026-2027); management declined to give forward guidance for the segment beyond the company's overall revenue growth guidance.

Innovative Medicines Grow 12.8%; Semaglutide and JAK Inhibitor Progress

• Innovative medicine sales of $351 million, up 12.8% — driven by Ilumya, Odomzo, and Sequa across both US and ex-US markets in Q1 FY 2026-2027; management confirmed both US and international markets continue to grow for innovative medicines.
• Consolidated R&D spend of Rs.8,264 million (5.4% of sales) — with ~30% allocated to innovative R&D and ~70% to generics and India-market products; management confirmed the FY 2026-2027 annual R&D spend target is on track.
• Semaglutide: #2 generic player in India; approvals in South Africa and Brazil — launched in India in March 2026, South Africa approval received in July 2026 (Q1 FY 2026-2027) with commercialization commenced; Brazil launch expected shortly via partner. Management expressed confidence in meeting FY 2026-2027 demand with in-house API and secured component supplies.
• Lexcelvi targeting large autoimmune indications — management is prioritizing indications where the product can differentiate (potentially vitiligo); investor-initiated trials are ongoing in the US and results will inform future clinical development. Management noted Lexcelvi is differentiated by speed and efficacy versus competitors.
• Partner Filogen resubmitted Nidlegji for marketing authorization in Europe — updated data publication is pending; this adds to the pipeline of innovative assets beyond the current portfolio.
• MM2 pipeline product (orthopedic pain/knee joints) to be out-licensed — management explained the company has no commercial presence in the US to cover orthopedicians/rheumatologists, making a partnership strategy the logical choice.

Gross Margin Strength Offsets Employee Cost Pressure; ETR Rises

• Employee costs rose ahead of revenue growth — CFO Jayshree Satagopan attributed this to three factors in Q1 FY 2026-2027: annual merit increments, additional field force deployed for two new product launches and expansion in non-US innovative medicine promotion, plus a forex impact that contributed to higher reported costs.
• Other expenses include ongoing launch costs — for Lexcelvi and Unloxet, along with forex translation effects; Mr. Astore corroborated that sustained investment is needed for successful launches and is not limited to one-time costs.
• Effective tax rate rose to 27.8% — versus 24.3% in Q1 FY 2025-2026, due to exhaustion of the lower India tax rate; management expects the ETR to stay in this range until the Organon transaction closes, while aiming to optimize the ETR.
• Consolidated net cash of $3.4 billion — balance sheet remains strong, providing financial flexibility ahead of the Organon acquisition closing.
• Depreciation and amortization decreased QoQ — in Q1 FY 2026-2027 with management indicating no specific reason for the decline.

Acquisition on Track for Q4 FY2027 Close; Revenue Guidance Reiterated

• Organon shareholder approval received — regulatory filings are complete in all markets, with approvals received in some countries; management expects the acquisition to close in Q4 FY 2026-2027 (early 2027).
• Exceptional items of Rs.1,670 million booked — for Organon acquisition-related costs in Q1 FY 2026-2027; additional charges are expected in subsequent quarters, with a substantial part at closing, not yet fully crystallized.
• Management reiterated high single-digit revenue growth guidance — for full-year FY 2026-2027, despite the current quarter reporting ~11% growth. CFO flagged a positive forex translation effect on revenue but advised sticking to the guidance range.
• Integration management office already active — working on day-one preparedness for the Organon acquisition; management directed unanswered questions to the investor relations team for follow-up.
• No product-level revenue guidance provided — management declined to disclose specific timelines for meaningful revenue contribution from Lexcelvi, Unloxet, or the payback period for innovative medicine marketing outlays.